Paul Slobbe

691 total citations · 1 hit paper
10 papers, 609 citations indexed

About

Paul Slobbe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Paul Slobbe has authored 10 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Paul Slobbe's work include Radiopharmaceutical Chemistry and Applications (5 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Paul Slobbe is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (5 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Paul Slobbe collaborates with scholars based in Netherlands, Germany and Austria. Paul Slobbe's co-authors include Romano V. A. Orrù, Eelco Ruijter, Alex J. Poot, Albert D. Windhorst, Guus A.M.S. van Dongen, G. Stehle, Egbert F. Smit, Flavio Solca, Marijke Stigter‐van Walsum and Robert C. Schuit and has published in prestigious journals such as The Journal of Organic Chemistry, Clinical Pharmacology & Therapeutics and Drug Discovery Today.

In The Last Decade

Paul Slobbe

10 papers receiving 606 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recent applications of multicomponent reactions in medicinal chemistry

2012 430 citations Paul Slobbe, Eelco Ruijter et al. MedChemComm profile →

Peers

Countries citing papers authored by Paul Slobbe

Since Specialization

Citations

This map shows the geographic impact of Paul Slobbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Slobbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Slobbe more than expected).

Fields of papers citing papers by Paul Slobbe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Slobbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Slobbe. The network helps show where Paul Slobbe may publish in the future.

Co-authorship network of co-authors of Paul Slobbe

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Slobbe. A scholar is included among the top collaborators of Paul Slobbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Slobbe. Paul Slobbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts 2017 ·Oncotarget ·Paul Slobbe, Albert D. Windhorst, (unknown), Marije Bolijn, Robert C. Schuit, Daniëlle A.M. Heideman, Guus A.M.S. van Dongen, Alex J. Poot	6
2	Two anti-angiogenic TKI-PET tracers, [ 11 C]axitinib and [ 11 C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents 2016 ·Nuclear Medicine and Biology ·Paul Slobbe, Alex J. Poot, (unknown), Robert C. Schuit, Albert D. Windhorst, Guus A.M.S. van Dongen	11
3	[11C]nintedanib as TKI-PET tracer for angiogenesis imaging in vivo. 2016 ·Alex J. Poot, Paul Slobbe, Albert D. Windhorst, (unknown), Robert C. Schuit, Guus A.M.S. van Dongen	1
4	A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice 2015 ·EJNMMI Research ·Paul Slobbe, Albert D. Windhorst, Marijke Stigter‐van Walsum, Egbert F. Smit, Heiko G. Niessen, Flavio Solca, G. Stehle, Guus A.M.S. van Dongen, Alex J. Poot	39
5	Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors 2014 ·Nuclear Medicine and Biology ·Paul Slobbe, Albert D. Windhorst, Marijke Stigter‐van Walsum, Robert C. Schuit, Egbert F. Smit, (unknown), Flavio Solca, G. Stehle, Guus A.M.S. van Dongen, Alex J. Poot	38
6	Diastereoselective One-Pot Synthesis of Tetrafunctionalized 2-Imidazolines 2014 ·The Journal of Organic Chemistry ·(unknown), Paul Slobbe, (unknown), (unknown), Andreas W. Ehlers, Célia Fonseca Guerra, F. Matthias Bickelhaupt, J. Chris Slootweg, Eelco Ruijter, Koop Lammertsma, Romano V. A. Orrù	5
7	Synthesis and Evaluation of a Selective Fluorogenic Pup Derived Assay Reagent for Dop, a Potential Drug Target in Mycobacterium tuberculosis 2012 ·ChemBioChem ·Remco Merkx, Kristin E. Burns, Paul Slobbe, Farid El Oualid, Dris El Atmioui, K. Heran Darwin, Huib Ovaa	13
8	PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET 2012 ·Drug Discovery Today ·Paul Slobbe, Alex J. Poot, Albert D. Windhorst, Guus A.M.S. van Dongen	55
9	Recent applications of multicomponent reactions in medicinal chemistry breakdown → 2012 ·MedChemComm ·Paul Slobbe, Eelco Ruijter, Romano V. A. Orrù	430
10	Imaging of TKI–Target Interactions for Personalized Cancer Therapy 2012 ·Clinical Pharmacology & Therapeutics ·Alex J. Poot, Paul Slobbe, N. Harry Hendrikse, Albert D. Windhorst, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact